Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: An updated systematic review and comparative meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 3, 2014, Pages 194-207

  Abdel Rahman, Omar ^a   Fouad, Mona ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Cardiovascular toxicities; Hypertension; Left ventricular dysfunction; Meta analysis; Sunitinib

Indexed keywords

AXITINIB; CEDIRANIB; REGORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

BLEEDING; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INDICATION; DRUG SAFETY; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; CARDIOVASCULAR DISEASES; COMPLICATION; NEOPLASMS; RISK;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; IMIDAZOLES; INCIDENCE; INDAZOLES; INDOLES; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; QUINAZOLINES; RISK;

EID: 84912532971     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.06.003     Document Type: Review

References (42)

1. Oudard S., Beuselinck B., Decoene J., et al. Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat Rev 2011, 37(May (3)):178-184. 10.1016/j.ctrv.2010.08.005.
2. Theou-Anton N., Faivre S., Dreyer C., et al. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer. Drug Saf 2009, 32(9):717-734. 10.2165/00002018-200932090-00003.
3. Sunitinib drug monograph, Sunitinib drug monograph; cancer care Ontario drug formulary;. https://www.cancercare.on.ca/toolbox/drugs/drugformulary.
4. Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J Egypt Natl Canc Inst 2013, 25(December (4)):165-171. 10.1016/j.jnci.2013.08.002.
5. Abdel-Rahman O. Exploring systemic options for advanced hepatocellular carcinoma 2013, LAP LAMBERT Academic Publishing, ISBN: 978-3-659-43013-8. 1st ed.
6. Pfizer pharma, Pfizer pharma, sutent prescribing information;. http://www.pfizer.ca/fr/our_products/products/monograph/147.
7. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009, 62(October (10)):1006-1012.
8. National cancer institute, common toxicity criteria;. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
9. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327(September (7414)):557-560.
10. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
11. Abdel-Rahman O., Elsayed Z. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci 2013, 58(December (12)):3389-3396. 10.1007/s10620-013-2872-x.
12. Demetri G.D., Reichardt P., Kang Y.K., et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381(January (9863)):295-302.
13. Négrier S., Gravis G., Pérol D., et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011, 12(July (7)):673-680.
14. Socinski M.A., Scappaticci F.A., Samant M., et al. Safety and efficacy of combining sunitinib with bevacizumab+paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol 2010, 5(March (3)):354-360.
15. Wildiers H., Fontaine C., Vuylsteke P., et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010, 123(September (2)):463-469.
16. Crown J.P., Diéras V., Staroslawska E., et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013, 31(August (23)):2870-2878.
17. Scagliotti G.V., Krzakowski M., Szczesna A., et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012, 30(June (17)):2070-2078.
18. Cheng A.L., Kang Y.K., Lin D.Y., et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013, 31(November (32)):4067-4075. 10.1200/JCO.2012.45.8372.
19. Bergh J., Bondarenko I.M., Lichinitser M.R., et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012, 30(March (9)):921-929.
20. Raymond E., Dahan L., Raoul J.L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(February (6)):501-513.
21. Mayer E.L., Dhakil S., Patel T., et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010, 21(December (12)):2370-2376.
22. Barrios C.H., Liu M.C., Lee S.C., et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121(May (1)):121-131.
23. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(January (2)):115-124.
24. Motzer R.J., Hutson T.E., Cella D., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013, 369(August (8)):722-731.
25. Kindler H.L., Loka T., Richel D.J., et al. Axitinib plus gemcitabine versusplaceb plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double blind randomized phase 3 study. Lancet Oncol 2011, 12(March (3)):256-262.
26. Motzer J., Escudier B., Tomczak P., et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013, 14(May (6)):552-562. 10.1016/S1470-20451370093-7.
27. Infante J.R., Reid T.R., Cohn A.L., et al. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. Cancer 2013, 119(July (14)):2555-2563. 10.1002/cncr.28112.
28. Rugo H.S., Stopeck A.T., Joy A.A., et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011, 29(June (18)):2459-2465. 10.1200/JCO.2010.31.2975.
29. Cunningham D., Wong R.P., D'Haens G., et al. Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. Br J Cancer 2013, 108(February (3)):493-502. 10.1038/bjc.2012.545.
30. Mulders P., Hawkins R., Nathan P., et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer 2012, 48(March (4)):527-537.
31. Goss G.D., Arnold A., Shepherd F.A., et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010, 28(January (1)):49-55. 10.1200/JCO.2009.22.9427.
32. Hoff P.M., Hochhaus A., Pestalozzi B.C., et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 2012, 30(October (29)):3596-3603. 10.1200/JCO.2012.42.6031.
33. Schmoll H.J., Cunningham D., Sobrero A., et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 2012, 30(October (29)):3588-3595. 10.1200/JCO.2012.42.5355.
34. Demetri G.D., Reichardt P., Kang Y.K., et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381(January (9863)):295-302. 10.1016/S0140-6736(12)61857-1.
35. Grothey A., Van Cutsem E., Sobrero A., Siena S., Falcone A., Ychou M. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381(January (9863)):303-312. 10.1016/S0140-6736(12)61900-X.
36. Abdel-Rahman O., Abdelwahab M., Shaker M., Abdelwahab S., Elbassiouny M., Ellithy M. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. J Egyptian Nat Cancer Inst 2014, 26(March (1)):9-14. 10.1016/j.jnci.2013.08.003.
37. Abdel-Rahman O., Abdelwahab M., Shaker M., Abdelwahab S., Elbassiouny M., Ellithy M. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013, 30(September (3)):655. 10.1007/s12032-013-0655-z.
38. Yoshiji H., Kuriyama S., Yoshii J., et al. halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004, 39:1517-1524.
39. Rini B.I., Cohen D.P., Lu D.R., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103(May (9)):763-773. 10.1093/jnci/djr128.
40. Je Y1, Schutz F.A., Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10(October (10)):967-974. 10.1016/S1470-2045(09)70222-0.
41. Huynh H., Ngo V.C., Choo S.P., et al. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr Cancer Drug Targets 2009, 9(September (6)):738-747.
42. Abdel-Rahman O., Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev Oncol Hematol 2014, pii:S1040-8428(13)00277-1. 10.1016/j.critrevonc.2013.12.013.